Frontlight ResearchEarly access
Not yet recruitingPhase 2
GA001 Injection in Retinitis Pigmentosa
Key facts
- Who runs it
- GenAns Biotechnology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 12 people, planned
- Starts
- 1 Apr 2027
- Expected to end
- 25 Nov 2031
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- GA001
- Sham injection
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female participants aged 18 to 70 years
- Clinical diagnosis of advanced retinitis pigmentosa (RP)
- Best corrected visual acuity at or below the protocol-defined threshold in the study eye
- Ability to understand and sign informed consent (and assent, when applicable)
- Laboratory test results are within the protocol-defined threshold range
Who cannot take part
- Presence of other ocular conditions that could interfere with study assessments
- History of significant ocular surgery in the study eye within a protocol-defined period
- Active ocular infection or inflammation
- Clinically significant systemic disease that could increase study risk or interfere with assessments
- Positive screening for clinically significant infectious diseases, as defined in the protocol
- Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation
- Pregnant or breastfeeding individuals
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.
The 2 groups in the trial
- GA001Treatment being tested
- Sham InjectionSham treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa
- Criteria questions
- Built from NCT07943312, who can take part
- Record updated
- 17 November 2026